XML 63 R17.htm IDEA: XBRL DOCUMENT
v3.25.1

Other financial assets | 12 Months Ended
--- | ---
Dec. 31, 2024
Disclosure of financial assets [abstract] |
Other financial assets | Other financial assets Other financial assets break down as follows:
(amounts in thousands of euros) | AS OF DECEMBER 31, 2022 |  | AS OF DECEMBER 31, 2023 |  | AS OF DECEMBER 31, 2024
OTHER FINANCIAL ASSETS |  |  |  |  |
Advances related to CRO contracts | 10,471 |  | 12,172 |  | 4,929
Deposits | 1,238 |  | 574 |  | 863
Other | — |  | 124 |  | 126
Total other non-current financial assets | 11,708 |  | 12,870 |  | 5,919
Advances related to CRO contracts | — |  | — |  | 7,418
Other investments | — |  | 9,050 |  | —
Deposits |  |  | 136 |  | 136
Total other current financial assets | — |  | 9,186 |  | 7,554
Other financial assets | 11,708 |  | 22,055 |  | 13,473
Advances related to CRO contracts These advances granted in 2022 for clinical studies are to be recovered at the end of the studies after final reconciliation with pass- through costs, which are being invoiced and paid as studies are carried out. These long-term advances were measured at fair value on initial recognition, using discount rates ranging from 0.19% to 7.16%, and are subsequently measured at amortized cost. During the first half of 2023, additional advances related to CRO contracts amounting to €1,620 thousand were made (undiscounted amount). These long-term advances were measured at fair value on initial recognition, using discount rates ranging from 7.09% to 7.59%, and are subsequently measured at amortized cost. At inception, a prepaid expenses asset was recognized for the difference between the advances’ nominal value and fair value, and spread over the term of the advances, at the rate of recognition of the related R&D expenses (see Note 10). In March 2024, a change order was signed with the CRO, extending the scope (addition of maintenance studies) and end date of one of the studies to 2029, thus postponing the recovery date of the corresponding advance of €5,538 thousand from June 2026 to June 2029. The Group considered that this asset modification met the criteria for derecognition, and recognized a new financial asset at fair value on that date, using a discount rate of 6.83%. Since the Group considers that these advances are made in exchange for a discount on future services to be received from the CROs, a prepaid expense asset was also recognized for the difference between the derecognized asset carrying value and new asset fair value, and spread over the term of the advance in a similar manner. The credit risk related to these advances is deemed insignificant due to the CROs' credit ratings. Other investments Other investments consist of 6-month term deposits that do not qualify for a classification under cash and cas h equivalents. Term deposits held by the Group as of December 31, 2024 qualify for a classification under cash equivalents. Deposits Deposits include the deposits paid under the Kreos 1 & 2 bond loans (reimbursed in August 2023), the liquidity agreement, the Paris and Boston offices lease contracts, the ATM Program, as well as other security deposits.

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfFinancialAssetsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of other assets. [Refer: Other assets] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfOtherAssetsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration